UNSPSC 51284141: Ceftazidime pentahydrate

This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9M416Z9QNR. European Medicines Agency schedules Ceftazidime pentahydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01134MIG. Ceftazidime generally arises in the molecular formula C22H22N6O7S2. The term 'ceftazidime' is a European Pharmacopoeia designation. CEFTAZIDIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations, for tariff and trade purposes, schedule ceftazidime pentahydrate under HS 29419000 and SITC 54139. SMILES: [H+].CC(C)(C(=O)[O-])O/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4CCCCC4)C(=O)[O-].O.O.O.O.O.

UNSPSC 51284141 Ceftazidime pentahydrate is a Commodity code that represents a specific injectable antibiotic pharmaceutical product. However, the recent state and local opportunities posted under this code do not align with ceftazidime procurement — instead, they reflect pharmaceutical warehouse supply contracts for unrelated products (oral antibiotics and naloxone) and community health initiatives. The code shows little relevant recent activity, with posted opportunities addressing different pharmaceutical categories than the ceftazidime compound this code nominally covers.

The two most recent opportunities tagged to this code originate from different issuing bodies and procurement contexts. The Illinois Department of Public Health posted a completed piggyback pharmaceutical warehouse award through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for doxycycline and ciprofloxacin (not ceftazidime), with a contract value of $2,999,999.11 over three years. Seminole County, Florida released an IFB in June 2026 for naloxone and drug deactivation systems, with quarterly deliveries to the county's Community Health Building and a two-year initial term plus one-year renewal option. The mismatch between the code's stated product scope and the actual pharmaceutical procurements posted under it suggests either tagging error or use of this code as a catch-all for pharmaceutical supply acquisitions. Readers pursuing opportunities in injectable antibiotics or ceftazidime specifically should verify coding accuracy directly with the issuing bodies before investing RFP response time.